AZD5863 is a bispecific T cell engager that binds Claudin 18.2 with high affinity and humanized CD3 with reduced affinity to limit cytokine release. In genO‑panhCD3 humanized mice, AZD5863 effectively inhibited tumor growth in CLDN18.2-expressing xenografts while minimizing systemic cytokine induction. The model supports selective T cell activation with strong anti-tumor potency and reduced toxicity profile.
Strong tumor growth inhibition with reduced cytokine release in vivo. Demonstrated bystander killing of antigen-negative tumor cells. Supports affinity modulation strategy for TCEs.
genO‑panhCD3 humanized Knockin mouse — genOway-developed, immunocompetent C57BL/6 background expressing humanized CD3edg
T cell engager therapy, CD3 bispecifics, immuno-oncology, Claudin 18.2 targeting, cytokine release mitigation, solid tumor models
Humanized CD3 epsilon delta gamma Knockin replacing murine Cd3 subunits, syngeneic or xenografted CLDN18.2+ tumors, AZD5863 treatment, pharmacodynamic tumor analysis, cytokine quantification, affinity-tuned bispecific antibody
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
